Shindo-Okada N - Search Results

1

Inhibition of chemical carcinogenesis in vivo by azatyrosine.

Izawa M, Takayama S, Shindo-Okada N, Doi S, Kimura M, Katsuki M, Nishimura S. Izawa M, et al. Cancer Res. 1992 Mar 15;52(6):1628-30. Cancer Res. 1992. PMID: 1540971

2

Azatyrosine inhibits neurite outgrowth of PC12 cells induced by oncogenic Ras.

Fujita-Yoshigaki J, Yokoyama S, Shindo-Okada N, Nishimura S. Fujita-Yoshigaki J, et al. Oncogene. 1992 Oct;7(10):2019-24. Oncogene. 1992. PMID: 1328988

3

Isolation of genes specifically expressed in flat revertant cells derived from activated ras-transformed NIH 3T3 cells by treatment with azatyrosine.

Krzyzosiak WJ, Shindo-Okada N, Teshima H, Nakajima K, Nishimura S. Krzyzosiak WJ, et al. Proc Natl Acad Sci U S A. 1992 Jun 1;89(11):4879-83. doi: 10.1073/pnas.89.11.4879. Proc Natl Acad Sci U S A. 1992. PMID: 1594588 Free PMC article.

4

Permanent conversion of NIH3T3 cells transformed by activated c-Ha-ras, c-Ki-ras, N-ras, or c-raf, and of human pancreatic adenocarcinoma containing activated c-Ki-ras to apparently normal cells by treatment with the antibiotic azatyrosine.

Shindo-Okada N, Makabe O, Nagahara H, Nishimura S. Shindo-Okada N, et al. Basic Life Sci. 1990;52:309-12. doi: 10.1007/978-1-4615-9561-8_26. Basic Life Sci. 1990. PMID: 2327940 No abstract available.

5

Permanent conversion of mouse and human cells transformed by activated ras or raf genes to apparently normal cells by treatment with the antibiotic azatyrosine.

Shindo-Okada N, Makabe O, Nagahara H, Nishimura S. Shindo-Okada N, et al. Mol Carcinog. 1989;2(3):159-67. doi: 10.1002/mc.2940020309. Mol Carcinog. 1989. PMID: 2675904

6

[Mechanism of action of azatyrosine: recent process].

Monden Y, Shindo-Okada N, Nishimura S. Monden Y, et al. Among authors: shindo okada n. Gan To Kagaku Ryoho. 1997 Sep;24(11):1563-70. Gan To Kagaku Ryoho. 1997. PMID: 9309155 Review. Japanese.

7

Azatyrosine. Mechanism of action for conversion of transformed phenotype to normal.

Monden Y, Hamano Takaku F, Shindo Okada N, Nishimura S. Monden Y, et al. Among authors: shindo okada n. Ann N Y Acad Sci. 1999;886:109-21. doi: 10.1111/j.1749-6632.1999.tb09406.x. Ann N Y Acad Sci. 1999. PMID: 10667209 Review.

8

Azatyrosine inhibits the activation of c-Raf-1, c-Jun and AP1 but not the activation of Ras during signal transduction triggered by oncogenic c-ErbB-2.

Monden Y, Nakamura T, Kojiri K, Shindookada N, Nishimura S. Monden Y, et al. Oncol Rep. 1996 Jan;3(1):33-40. doi: 10.3892/or.3.1.33. Oncol Rep. 1996. PMID: 21594311

9

The antibiotic, L-beta-(5-hydroxy-2-pyridyl)-alanine specifically inhibits growth of the NIH3T3 cells transformed by activated human c-Ha-ras and induces formation of flat revertant cells.

Shindo-Okada N, Nagahara H, Yamaizumi Z, Makabe O, Nishimura S. Shindo-Okada N, et al. Nucleic Acids Symp Ser. 1988;(19):129-30. Nucleic Acids Symp Ser. 1988. PMID: 3067212 No abstract available.

10

Stimulation of the expression of rhoB contributes to the ability of azatyrosine to convert c-erbB-2-transformed cells to a normal morphology.

Monden Y, Nakamura T, Kojiri K, Shindookada N, Nishimura S. Monden Y, et al. Oncol Rep. 1996 Jan;3(1):49-55. doi: 10.3892/or.3.1.49. Oncol Rep. 1996. PMID: 21594314

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

33 results

Search Page

Filters